Abstract: Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alpha3 chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient.

Abstract: Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alphas chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient.

Abstract: Antibody antigen binding domains which specifically binds human leptin comprises VH or VL CDR1, CDR2 and CDR3 sequences of an hLept antibody. The antibody antigen binding domains and antibodies thereof are useful to treat obesity and diabetes.

Abstract: Antibody antigen binding domains which specifically binds human leptin comprises VH or VL CDR1, CDR2 and CDR3 sequences of an hLept antibody. The antibody antigen binding domains and antibodies thereof are useful to treat obesity and diabetes.

Abstract: Obesity and/or diabetes are treated by partially inhibiting circulating leptin in a person in need thereof.

Abstract: Antibody antigen binding domains which specifically binds human leptin comprises VH or VL CDR1, CDR2 and CDR3 sequences of an hLept antibody. The antibody antigen binding domains and antibodies thereof are useful to treat obesity and diabetes.

Abstract: Antibody antigen binding domains which specifically binds human leptin comprises VH or VL CDR1, CDR2 and CDR3 sequences of an hLept antibody. The antibody antigen binding domains and antibodies thereof are useful to treat obesity and diabetes.

Abstract: Obesity and/or diabetes are treated by partially inhibiting circulating leptin in a person in need thereof.

Abstract: Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alphas chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient.

Abstract: Obesity and/or diabetes are treated by partially inhibiting circulating leptin in a person in need thereof.

Abstract: Antibody antigen binding domains which specifically binds human leptin comprises VH or VL CDR1, CDR2 and CDR3 sequences of an hLept antibody. The antibody antigen binding domains and antibodies thereof are useful to treat obesity and diabetes.

Abstract: Methods of determining whether a cancer is progressing by measuring surface-bound collagen VI?3 are provided. Also provided are methods of identifying hyperplasia in a tissue by measuring surface-bound collagen VI?3. Additionally, methods of identifying carcinoma in a tissue by measuring surface-bound collagen VI?3 are provided. Further provided are methods of imaging carcinoma in a tissue by staining the tissue with a specific binding partner to collagen VI?3. Methods of treating a cancer by preventing binding of collagen VI?3 onto cells of the cancer are additionally provided.

Abstract: Methods of determining whether a cancer is progressing by measuring surface-bound collagen VI?3 are provided. Also provided are methods of identifying hyperplasia in a tissue by measuring surface-bound collagen VI?3. Additionally, methods of identifying carcinoma in a tissue by measuring surface-bound collagen VI?3 are provided. Further provided are methods of imaging carcinoma in a tissue by staining the tissue with a specific binding partner to collagen VI?3. Methods of treating a cancer by preventing binding of collagen VI?3 onto cells of the cancer are additionally provided.

Abstract: The present invention relates to DNA encoding Acrp30, of vertebrate (e.g., mammalian) origin, and particularly of human and rodent origin. The present invention further relates to isolated, recombinantly produced or synthetic DNA which hybridizes to the nucleotide sequences described herein and RNA transcribed from the nucleotides sequence described herein. In addition, the invention relates to expression vectors comprising DNA encoding Acrp30, which is expressed when the vector is present in an appropriate host cell. The invention further relates to isolated, recombinantly produced or synthetic mammalian Acrp30 of vertebrate (e.g., mammalian) origin, and particularly of human and rodent origin. Also encompassed by the present invention is an inhibitor or enhancer of Acrp30. The present invention further relates to a method of identifying inhibitors or enhancers of Acrp30. Isolation of Acrp30 makes it possible to detect Acrp30 or adipocytes in a sample (e.g., test sample).